# Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension

Study · id `cardio:ct-nct05165251` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05165251](<https://clinicaltrials.gov/study/NCT05165251>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05165251

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 480 participants.

## Technical summary

Registry record NCT05165251. Randomized; no masking; primary purpose treatment. Start 2022-01-04 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 480 participants (planned count; ClinicalTrials.gov record NCT05165251, source copy `cardio:ctgov-nct05165251-2023-02-15`, retrieved 2026-10-26)
- Started: 2022-01-04 (actual) (ClinicalTrials.gov record NCT05165251, source copy `cardio:ctgov-nct05165251-2023-02-15`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05165251, source copy `cardio:ctgov-nct05165251-2023-02-15`, retrieved 2026-10-26)
- Completion: 2025-06-01 (anticipated) (ClinicalTrials.gov record NCT05165251, source copy `cardio:ctgov-nct05165251-2023-02-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05165251, source copy `cardio:ctgov-nct05165251-2023-02-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05165251-2023-02-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension
- Condition: Isolated Systolic Hypertension
- Intervention (Drug): Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET
- Intervention (Drug): Amlodipine 5mg
- Intervention (Other): Lifestyle intervention
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)

## Provenance

Content hash: e8816b4ce5e4659966fd3cc1adea675b22f13105c6a45fb63bc07167508ecd05
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
